Overview

Study in Subjects With Moderate Atopic Dermatitis

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Ralexar Therapeutics, Inc.